Recent Quotes (30 days)

You have no recent quotes
chg | %

PDL BioPharma Inc  

(Public, NASDAQ:PDLI)   Watch this stock  
Find more results for PDLI
-0.05 (-1.76%)
After Hours: 2.80 +0.01 (0.33%)
Jan. 16, 4:47p.m. EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.78 - 2.89
52 week 1.96 - 3.55
Open 2.83
Vol / Avg. 1.06M/1.40M
Mkt cap 430.61M
P/E 5.54
Div/yield     -
EPS 0.50
Shares 154.34M
Beta 0.46
Inst. own 91%
Feb. 21, 2018
Q4 2017 PDL BioPharma Inc Earnings Release (Estimated) - 4:00p.m. EST - Add to calendar
Nov. 28, 2017
PDL BioPharma Inc at Piper Jaffray Healthcare Conference
Nov. 15, 2017
PDL BioPharma Inc at Jefferies Global Healthcare Conference
Nov. 2, 2017
Q3 2017 PDL BioPharma Inc Earnings Call - Webcast
Nov. 2, 2017
Q3 2017 PDL BioPharma Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep. '17) 2016
Net profit margin 33.04% 26.06%
Operating margin 48.36% 52.01%
EBITD margin - 81.79%
Return on average assets 6.58% 5.72%
Return on average equity 10.13% 8.79%
Employees 11 -
CDP Score - -


932 Southwood Blvd
United States - Map
+1-775-8328500 (Phone)
+1-775-8328501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.

Officers and directors

Dominique Monnet President
Age: 59
Bio & Compensation  - Reuters
John Peter McLaughlin Chief Executive Officer, Director
Age: 65
Bio & Compensation  - Reuters
Peter S. Garcia Chief Financial Officer, Vice President
Age: 55
Bio & Compensation  - Reuters
Steffen Pietzke CPA Chief Accounting Officer, Vice President - Finance
Age: 44
Bio & Compensation  - Reuters
Christopher Lewis Stone J.D. Vice President, General Counsel, Secretary
Age: 52
Bio & Compensation  - Reuters
Harold E. Selick Ph.D. Lead Independent Director
Age: 62
Bio & Compensation  - Reuters
Paul R. Edick Independent Director
Age: 62
Bio & Compensation  - Reuters
David W. Gryska Independent Director
Age: 61
Bio & Compensation  - Reuters
Jody S. Lindell Independent Director
Age: 65
Bio & Compensation  - Reuters
Samuel R. Saks M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters